secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-173983
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian reports cash of $563.4M; BLA for veligrotug on track for 2H 2025
-------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments $563.4M as of June 30, 2025, down from $636.6M at March 31, 2025; runway into 2H 2027.
- R&D expenses $86.6M in Q2 2025 (up from $56.2M in Q2 2024) driven by more clinical trials and higher headcount.
- Veligrotug BLA submission on track for 2H 2025; U.S. commercial launch anticipated in 2026 if approved.
- Exclusive license with Kissei for Japan: $70M upfront, up to $315M in milestones, plus tiered royalties.
- Veligrotug durability data: 70% of proptosis responders at week 15 maintained response at week 52.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/0001193125-25-173983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/d20477d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer